Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, December 9 at 2:00 PM ET

Register Free →

This Justification (J&A) opportunity from New Mexico was posted on January 24, 2025. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Gene Therapy Solutions for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy Treatments

Awarded
50-U6900-25-CP035State & Local

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325414
DIBBS
MEDICAL PHARMACY EMERGENCY NON NSN ORDER
Solicitation # SPE2DP-26-R-0004
Solicitation SPE2DP-26-R-0004 is a Request for Proposal issued on November 4, 2026, by the Department of Defense Medical Supply Chain Pharmacy FSA for the procurement of egg-free Influenza Virus Vaccine, 2027-2028 Formula for adults aged 18 and older. The government intends to award a Firm Fixed Price, Indefinite Delivery, Indefinite Quantity contract to the responsible offeror determined to be most advantageous based on price and non-price factors. Proposals must be submitted electronically via the DIBBS system by December 3, 2026. Award criteria include the proposed unit and total price, agreement to all solicitation terms without exception, and, for large businesses, the submission of a Small Business Subcontracting Plan. The contract mandates strict quality and cold chain management standards, requiring vaccines to be maintained between 2 to 8 degrees Celsius during transportation for up to 72 hours with no acceptable excursions. Products must be delivered to DLA Distribution Susquehanna in New Cumberland, Pennsylvania, and must have an expiration date no later than 18 months after the date of issue from the manufacturer's cold storage. Manufacturers must be FDA current Good Manufacturing Practice acceptable. Packaging and marking must adhere to Medical Marking Standard No. 1D and MIL-STD-129 for perishables. Invoicing and payment will be processed electronically through the Wide Area Workflow system.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

13 days ago

DEADLINE

in 16 days

AI Contract Overview

Show more

This contract involves the procurement of gene therapy solutions aimed at treating Duchenne Muscular Dystrophy and Spinal Muscular Atrophy through intravenous infusions. The project is led by the University of New Mexico Hospital, a state-level organization, with a funding range estimated between 14 million and 16 million dollars. The primary focus is on acquiring advanced gene therapy drugs that can effectively address these severe neuromuscular disorders, providing potentially life-changing treatment options for affected patients. The solicitation was posted on January 24, 2025, with a response deadline set for February 22, 2025. Interested vendors are encouraged to submit their proposals by this date. The contract emphasizes the importance of delivering innovative gene therapy treatments within the specified budget range, ensuring compliance with healthcare standards and patient safety. For further details or inquiries, the designated purchasing contact is Cherrin, reachable via email at [email hidden] or by phone at [phone hidden].

General Info

Documents

1
PDF, Low priorityjustification-and-authorization
Low

Read the document

Every page of every file, in your free workspace.

Read the document

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

View Full Breakdown

This one is closed. Find the next one like it.

Open contracts like this one, right now:

  • Purified Antibody Production and ScalingOpen now, due in 13 days
  • Biological Feedstock SupplyOpen now, due in 66 days
See open contracts like this

Ask CLEATUS

I've read this contract. Ask me anything.

Timeline

PhaseAwarded
Posted

Solicitation

Awarded

Contract was awarded

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyUniversity Of New Mexico/Hospital
Contacts1 person available
OfficeN/A

Full Description

Show more
GENE THERAPY DRUG TREATS DUCHENNE MUSCULAR DYSTROPHY. IV INFUSION. GENE THERAPY DRUG THAT TREATS SPINAL MUSCULAR ATROPHY.

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS